Clin Oncol J. 2020;2(1):TCOJ-02-1006 | Open Access
Solafa Omer Bushra Himedan and Mohammed Ibrahim Hassan
Background: Breast cancer is the most common cancer among women in Sudan and over the world. The concerning mainly was on clinical management but health-related quality of life now is thought to be an important endpoint in clinical trials. Assessing the quality of life in cancer patients contribute to increase the value of treatment and could play a role as ... Read more
RESEARCH ARTICLE Updated Apr 21, 2020 PDF
Clin Oncol J. 2019;1(1):TCOJ-01-1005 | Open Access
Mohamed Abdallah Mohamed, Azza Mustafa Aljaali, and Mohamed Ibrahim Hassan Ibrahim
Objective: To review studies published concerning Sexual Dysfunction among female patients with breast cancer.
Methods: Electronic databases SCIENCE DIRECT, PUBMED, CINAHL, EBSCO, SCOPUS, and UPTODATE have been searched
to identify relevant studies, 3 studies selected after appraisal.
Results: Sexual Dysfunction among female patients with breast cancer is common and it is not well recognized, the medical staff
at breast cancer clinics ... Read more
REVIEW ARTICLE Updated Dec 16, 2019 PDF
Clin Oncol J. 2019;1(1):TCOJ-01-1004 | Open Access
Qiu Min, Sheng Nan Cao, Ya Ping Gan, Tie Shan Song, Fu Xing Liu and Zhi Feng Ning
Objective: Establish a human drug-resistant bladder cancer cell line (T24/MMC), which are integral to the initiation, high recurrence and chemo-resistance of bladder cancer. BCSCs are heterogeneous and originate from multiple cell types, including urothelial stem cells and differentiated cell types, including basal, intermediate stratum and umbrella cells, then investigate its characteristics.
Methods: Human bladder ... Read more
RESEARCH ARTICLE Updated Jun 14, 2019 PDF
Clin Oncol J. 2018;1(1):TCOJ-01-1003 | Open Access
Nicola Gentili and Mattia Altini
Nowadays, computer technology pervades the daily life of a large number of people: in a few years the development of the Internet has led to connect over 23 million devices worldwide and over 4 million people beyond 50% of the inhabitants of the earth.
Read more
EDITORIAL Updated Oct 15, 2018 PDF
Clin Oncol J. 2018;1(1):TCOJ-01-1002 | Open Access
Zahra Mozaheb
Treatment options for Chronic Myeloid Leukemia (CML) have changed dramatically during the last decades. Imatinib become the first line treatment of chronic myeloid leukemia in chronic and accelerated phase. Several clinical trials with imatinib have largely demonstrated the drug to be well tolerated in humans and common side effects usually manageable. With longer follow-up we are able to evaluate rarer ... Read more
MINI REVIEW Updated Oct 16, 2018 PDF
